Fasken
Fasken is a prominent Canadian law firm that was established in 1862 and is headquartered in Toronto. With over 700 lawyers and ten offices across four continents, Fasken offers a comprehensive range of legal services. Its practice areas encompass competition and marketing, corporate finance, corporate social responsibility, estate planning, government relations, indigenous law, and investment management. The firm serves a diverse clientele, providing legal expertise to sectors including cannabis, construction, energy, financial services, healthcare, infrastructure, insurance, life sciences, and real estate.
Pro Bono Ontario (PBO) bridges the gap between lawyers who want to donate their services and low-income Ontarians who cannot afford a lawyer or qualify for legal aid.
Asmacure Ltée is a clinical-stage biopharmaceutical company focused on the development of novel, proprietary compounds that target cholinergic receptors for the treatment of inflammation, notably pulmonary airway diseases. The company’s lead compound, ASM-024, has a novel multi-functional mechanism of action with nicotinic and muscarinic effects. ASM-024 has demonstrated the capabilities of anti-inflammation, bronchoprotection, and smooth muscle relaxation in pre-clinical asthma models. Administered as a solution for nebulization in asthma patients, ASM-024 demonstrated clinical proof of concept in a phase 2 trial with significant effects on FEV1 and methacholine PC20. Asmacure has advanced ASM-024 into the clinic for the treatment of moderate asthma and COPD with a dry powder for inhalation (DPI) formulation. The DPI is a preferred dosage form for many patients and should allow ASM-024 to be delivered with greater lung deposition yielding the potential for a lower and more optimal dose. Asmacure was founded by Dr. Yvon Cormier, a noted pulmonologist, and Dr Evelyne Israel-Assayag in 2002 and is based in Quebec City, Quebec, Canada.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.